RxDoctor Payments Data

Jonathan Godfrey, MD

Gastroenterology · Pocatello, IDNPI 1649474719

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 34.1% of the total. Reporting peaked in 2019 at $293 and has fallen 69.4% since, to $90 in 2025. That places this record below the midpoint for gastroenterology clinicians in ID, where the typical reported total is $1,538.

$575in general payments, 2019–2025

Across 34 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$99
  • Pfizer$62
  • Pentax Of America, Inc.$43
  • Gilead$41
  • Boston Scientific$25
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$575 in reported general payments places this provider in the 30th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$92,039
Medicare patients
382
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase13$49,463
LinzessLinaclotide13$6,643
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl127$2,300
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates31$1,969
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl140$1,945
Omeprazole183$1,404
Pantoprazole Sodium156$1,262
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl75$873
Famotidine41$438
Dicyclomine Hcl15$209
Amitriptyline Hcl22$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$196$6,64313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →